SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Bookman MA. Developmental chemotherapy and management of recurrent ovarian cancer. J Clin Oncol. 2003; 21: 149s-167s.
  • 2
    Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006; 95: S161-S192.
  • 3
    Modesitt SC, Jazaeri AA. Recurrent epithelial ovarian cancer: Pharmacotherapy and novel therapeutics. Expert Opin Pharmacother. 2007; 8: 2293-2305.
  • 4
    Genentech. Avastin (bevacizumab) prescribing Information. South San Francisco, CA: Genentech; 2009.
  • 5
    Burger RA, Brady MF, Bookman MA, et al. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study [abstract]. J Clin Oncol. 2010; 28( 15s):946s. Abstract LBA1.
  • 6
    Perren T, Swart AM, Pfisterer J, et al. ICON7: A phase III randomised Gynaecologic Cancer InterGroup trial of concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab, versus chemotherapy alone in women with newly diagnosed epithelial ovarian (EOC), primary peritoneal (PPC) or fallopian tube cancer (FTC) [abstract]. Ann Oncol. 2010; 21( suppl 8): vii2-vii3. Abstract LBA4.
  • 7
    Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group Study. J Clin Oncol. 2007; 25: 5165-5171.
  • 8
    Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007; 25: 5180-5186.
  • 9
    Garcia AA, Hirte H, Fleming G, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol. 2008; 26: 76-82.
  • 10
    Aghajanian C, Sill MW, Darcy K, et al. A phase II evaluation of bevacizumab in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group (GOG) Study [abstract]. J Clin Oncol. 2009; 27( 18s):284s. Abstract 5531.
  • 11
    Monk BJ, Sill MW, Burger RA, Gray HJ, Buekers TE, Roman LD. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study. J Clin Oncol. 2009; 27: 1069-1074.
  • 12
    GlaxoSmithKline. Hycamtin (topotecan hydrochloride) prescribing information. Research Triangle Park, NC: Glaxo SmithKline; 2010.
  • 13
    Homesley HD, Hall DJ, Martin DA, et al. A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients. Gynecol Oncol. 2001; 83: 394-399.
  • 14
    Bhoola SM, Coleman RL, Herzog T, et al. Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer. Gynecol Oncol. 2004; 95: 564-569.
  • 15
    Safra T, Menczer J, Bernstein R, et al. Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer. Gynecol Oncol. 2007; 105: 205-210.
  • 16
    Abushahin F, Singh DK, Lurain JR, Grendys EC, Rademaker AW, Schink JC. Weekly topotecan for recurrent platinum resistant ovarian cancer. Gynecol Oncol. 2008; 108: 53-57.
  • 17
    Morris R, Alvarez RD, Andrews S, et al. Topotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal cancers. Gynecol Oncol. 2008; 109: 346-352.
  • 18
    Clements MK, Jones CB, Cumming M, Daoud SS. Antiangiogenic potential of camptothecin and topotecan. Cancer Chemother Pharmacol. 1999; 44: 411-416.
  • 19
    O'Leary JJ, Shapiro RL, Ren CJ, Chuang N, Cohen HW, Potmesil M. Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model. Clin Cancer Res. 1999; 5: 181-187.
  • 20
    Rustin GJ. Use of CA-125 to assess response to new agents in ovarian cancer trials. J Clin Oncol. 2003; 21( 10 suppl): 187s-193s.
  • 21
    Mutch DG, Orlando M, Goss T, et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2007; 25: 2811-2818.
  • 22
    O'Byrne KJ, Bliss P, Graham JD, et al. A phase III study of Doxil/Caelyx versus paclitaxel in platinum-treated, taxane-naive relapsed ovarian cancer [abstract]. Proc Am Soc Clin Oncol. 2002; 21: 203a. Abstract 808.
  • 23
    Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001; 19: 3312-3322.
  • 24
    Verschraegen C, Muller C, Rutledge T, et al. Preliminary efficacy and safety of pegylated liposomal doxorubicin and bevacizumab in patients with platinum resistant or intolerant ovarian cancer: Initial results of a phase 2 trial. Presented at: International Gynecologic Cancer Society 12th Biennial Meeting, Bangkok, Thailand, October 25-28, 2008.
  • 25
    Kikuchi Y Sr, Kouta H, Kikuchi R, et al. Effects of weekly bevacizumab and pegylated liposomal doxorubicin in heavily pretreated patients with recurrent or progressed ovarian cancer [abstract]. J Clin Oncol. 2009; 27: 15s. Abstract 5547.
  • 26
    Richardson DL, Backes FJ, Hurt JD, et al. Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab? Gynecol Oncol. 2010; 118: 47-51.
  • 27
    Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: A meta-analysis. Lancet Oncol. 2009; 10: 559-568.
  • 28
    Seamon LG, Richardson DL, Hurt JD, et al. Bevacizumab and weekly topotecan as salvage chemotherapy for ovarian cancer [abstract]. Gynecol Oncol. 2009; 112: S57. Abstract 112.
  • 29
    Sfakianos GP, Numnum TM, Halverson CB, Panjeti D, Kendrick JE IV, Straughn JM Jr. The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: A retrospective cohort study. Gynecol Oncol. 2009; 114: 424-426.
  • 30
    Stone RL, Sood AK, Coleman RL. Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer. Lancet Oncol. 2010; 11: 465-475.
  • 31
    Bono P, Elfving H, Utriainen T, et al. Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma. Ann Oncol. 2009; 20: 393-394.
  • 32
    Ryanne Wu R, Lindenberg PA, Slack R, Noone A, Marshall JL, He AR. Evaluation of hypertension as a marker of bevacizumab efficacy. J Gastrointest Cancer. 2009; 40: 101-108.
  • 33
    Hurwitz H, Douglas PS, Middleton JP, et al. Analysis of early hypertension (HTN) and clinical outcome with bevacizumab (BV) [abstract]. J Clin Oncol. 2010; 28( 15s): 242s. Abstract 3039.